Trials / Completed
CompletedNCT04351100
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 34 (actual)
- Sponsor
- Chulalongkorn University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Dry eyes is multi-factorial disease which inflammation play etiological role. Diacerein is drug which has anti-inflammatory effect by antagonist Interleukin-1, decrease Interleukin-1 receptor, increase Interleukin-1 Receptor antagonist. This observational study enrolled participants who going to take diacerein for osteoarthritis, measure corneal staining score, Ocular surface disease index score, Tear Osmolarity, Tear break up time, Schirmer 1 test, Interleukin-1 Receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear at the time of enrollment and after 2 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Diacerein | Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months. |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2020-07-31
- Completion
- 2020-07-31
- First posted
- 2020-04-17
- Last updated
- 2021-08-10
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT04351100. Inclusion in this directory is not an endorsement.